2-(叔丁氧羰基)环丙烷甲酸 | 1083181-22-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-(叔丁氧羰基)环丙烷甲酸
• 英文名称: 2-((tert-Butoxycarbonyl)amino)cyclopropanecarboxylic acid
• 英文别名: 2-[(2-methylpropan-2-yl)oxycarbonylamino]cyclopropane-1-carboxylic acid
• CAS: 1083181-22-9；1810070-30-4
• 化学式: C₉H₁₅NO₄
• mdl: MFCD11558998
• 分子量: 201.22
• InChiKey: NOZMNADEEKQWGO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.777
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS<br/>[FR] DÉRIVÉS DE LA PYRIDAZINE INHIBITEURS DU FACTEUR XIA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2009114677A1

  公开（公告）日：2009-09-17

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein the variables A, L1, L2, R2, R11, and M are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了式（I）的化合物：或其立体异构体、互变异构体或药学上可接受的盐，其中变量A、L1、L2、R2、R11和M如本文所定义。这些化合物是选择性因子XIa抑制剂或fXIa和血浆激肽原的双重抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。
• Cyclic and bicyclic diamino histamine-3 receptor antagonists
  申请人：——

  公开号：US20010049367A1

  公开（公告）日：2001-12-06

  Compounds of formula (I) 1 compounds of formula (II) 2 compounds of formula (III) 3 and compounds of formula (IV) 4 or pharmaceutically acceptable salts thereof are useful as H 3 receptor antagonists. Processes to make the compounds and methods of treatment using the compounds are also disclosed.

  化合物的公式(I)1、公式(II)2、公式(III)3和公式(IV)4或其药学上可接受的盐被用作H3受体拮抗剂。还公开了制备这些化合物的方法以及使用这些化合物的治疗方法。
• [EN] INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30<br/>[FR] INHIBITION DE LA PEPTIDASE 30 SPÉCIFIQUE DE L'UBIQUITINE
  申请人：FORMA THERAPEUTICS INC

  公开号：WO2019071073A1

  公开（公告）日：2019-04-11

  The present disclosure relates to chemical entities useful as inhibitors of Ubiquitin Specific Peptidase 30 (USP30), pharmaceutical compositions comprising the chemical entities, and methods of using the chemical entities. The chemical entities as disclosed herein can be useful in the treatment of a disease, disorder, or condition involving mitochondrial dysfunction, including neurodegenerative diseases, motor neuron diseases, metabolic disorders, and cancers, among other ailments.

  本公开涉及作为泛蛋白特异性蛋白酶30（USP30）抑制剂的化学实体，包括含有这些化学实体的药物组合物，以及使用这些化学实体的方法。本公开所述的化学实体可用于治疗涉及线粒体功能障碍的疾病、疾病或疾病，包括神经退行性疾病、运动神经元疾病、代谢紊乱和癌症等疾病。
• ORNITHINE DERIVATIVE
  申请人：Astellas Pharma Inc.

  公开号：EP2141147A1

  公开（公告）日：2010-01-06

  Provided is a compound which is useful as a therapeutic agent for chronic renal insufficiency and a therapeutic agent for diabetic nephropathy. The present inventors have made extensive studies on an ornithine derivative having an antagonistic action against an EP4 receptor, and as a result, they have found that by introducing cycloalkanediyl at a C terminal of the ornithine part of the compound of the present invention, the physicochemical properties such as solubility, and the like can be improved, thereby giving further preferred properties as a pharmaceutical. Therefore, they have completed the present invention. The compound of the present invention exhibits a good antagonistic action against an EP4 receptor, and thus, it is useful as a therapeutic agent for chronic renal insufficiency and diabetic nephropathy.

  提供了一种化合物，可用作慢性肾功能不全的治疗剂和糖尿病肾病的治疗剂。目前的发明人对具有对EP4受体拮抗作用的鸟氨酸衍生物进行了广泛研究，结果发现通过在目前发明的化合物的鸟氨酸部分的C末端引入环烷基，可以改善物理化学性质，如溶解性等，从而赋予其作为药物的更优越性质。因此，他们完成了这项发明。目前发明的化合物对EP4受体表现出良好的拮抗作用，因此，它可用作慢性肾功能不全和糖尿病肾病的治疗剂。
• 4-PHENYLTHIAZOLE AND 4-PHENYLIMIDIZOLE DERIVATIVES AND THEIR USE AS MEDICAMENTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES, PAIN AND EPILEPSY
  申请人：CHABRIER de LASSAUNIERE Pierre-Etienne

  公开号：US20080108683A1

  公开（公告）日：2008-05-08

  The invention relates to novel derivatives of 4-phenylthiazoles and 4-phenylimidizoles and the use thereof as medicaments. The invention especially relates to the following compounds: butyl-2-[4-(4-aminophenyl)-1H-imidizol-2-yl]ethyl-carbamate, and 4-[2-(1-aminocyclopentyl)-1,3-thiazol-4-yl]-2,6-di-tert-butylphenol, and the salts of the same.

  本发明涉及4-苯基噻唑和4-苯基咪唑的新衍生物及其作为药物的用途。本发明特别涉及以下化合物：丁基-2-[4-(4-氨基苯基)-1H-咪唑-2-基]乙基-氨基甲酸酯，以及4-[2-(1-氨基环戊基)-1,3-噻唑-4-基]-2,6-二叔丁基苯酚及其盐。